Novartis to buy US gene therapy group AveXis for $8.7 bn

Novartis in January reported that strong sales of two of its main blockbuster drugs enabled it to turn in a "good operation
Novartis in January reported that strong sales of two of its main blockbuster drugs enabled it to turn in a "good operational performance" in 2017.

Swiss pharmaceuticals giant Novartis announced Monday it will buy US gene therapy company AveXis for $8.7 billion (7.1 billion euros).

It said the all-cash deal was approved unanimously by the boards of both firms.

The Illinois-based AveXis is involved in for the treatment of (SMA), a rare neurodegenerative disease caused by a defect in a single gene.

"The proposed acquisition of AveXis offers an extraordinary opportunity to transform the care of SMA," Novartis CEO Vas Narasimhan was quoted as saying in a company statement.

"The acquisition would also accelerate our strategy to pursue high-efficacy, first-in-class therapies and broaden our leadership in neuroscience."

The announcement comes less than two weeks after Novartis said it will sell its stake in its consumer healthcare joint venture to Britain's GlaxoSmithKline for $13 billion.

The group said the sale of the 36.5 percent stake will enable it "to further focus on the development and growth of its core businesses."

Novartis in January reported that strong sales of two of its main blockbuster drugs enabled it to turn in a "good operational performance" in 2017.

Net profit climbed by 15 percent to $7.7 billion in 2017 on a one-percent increase in sales to $49.1 billion.


Explore further

Novartis to buy back $5 bn in shares

© 2018 AFP

Citation: Novartis to buy US gene therapy group AveXis for $8.7 bn (2018, April 9) retrieved 17 September 2019 from https://medicalxpress.com/news/2018-04-novartis-gene-therapy-group-avexis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more